Advertisement
Screener

ELI LILLY AND COMPANY (LLY) Debt / Equity

ELI LILLY AND COMPANY (LLY) Debt / Equity

  • 2014-03-31: Debt/Equity Ratio 0.34.
  • 2013-12-31: Debt/Equity Ratio 0.3.
  • 2013-09-30: Debt/Equity Ratio 0.31.
  • 2013-06-30: Debt/Equity Ratio 0.35.

Complete source-backed debt/equity ratio history.

Available history
2008-12-31 to 2014-03-31
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2014-03-310.34
2013-12-310.3
2013-09-300.31
2013-06-300.35
2013-03-310.37
2012-12-310.37
2012-09-300.34
2012-06-300.39
2012-03-310.37
2011-12-310.52
2011-09-300.47
2011-06-300.47
2011-03-310.48
2010-12-310.55
2010-09-300.58
2010-03-310.64
2009-12-310.69
2009-09-300.75
2009-06-300.9
2008-12-311.55

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2013-12-310.3
2012-12-310.37
2011-12-310.52
2010-12-310.55
2009-12-310.69
2008-12-311.55

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94